-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 FbO9pgS5kiSE46urqzTSQBG2ZaGcR86WqEPDtocSBslKOXPj6kTu5WEiSEcSys9E
 87yhvOPQueusUjuJlGG14Q==

<SEC-DOCUMENT>0001129928-09-000007.txt : 20090316
<SEC-HEADER>0001129928-09-000007.hdr.sgml : 20090316
<ACCEPTANCE-DATETIME>20090316125713
ACCESSION NUMBER:		0001129928-09-000007
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090316
FILED AS OF DATE:		20090316
DATE AS OF CHANGE:		20090316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		09683297

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<TEXT>
<html>
  <head>
    <title>form6-k.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div><br><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report
of Foreign Private Issuer</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule&#160;13a-16 or 15d-16</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
the Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the
month of&#160;March 2009</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
File Number 000-31062</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Oncolytics
Biotech Inc.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suite&#160;210,
1167 Kensington Crescent NW</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Calgary,
Alberta, Canada T2N 1X7</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Address
of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover Form&#160;20-F or Form&#160;40-F.</font></div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="38%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
              </td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="38%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form&#160;6-K in paper as
permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if
submitted solely to provide an attached annual report to security
holders.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form&#160;6-K in paper as
permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if
submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form&#160;6-K submission or other
Commission filing on EDGAR.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="38%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Yes&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
              </td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="38%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">No&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EXHIBIT</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NUMBER</font></div>
              </td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DESCRIPTION</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
              </td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="69%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">News
      Release Dated March 16, 2009 -&#160;Oncolytics Biotech&#174; Inc. Announces
      Reovirus Research to be Presented at AACR Annual Meeting</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" colspan="3" valign="top" width="39%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics
      Biotech Inc.</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Registrant)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="38%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:&#160;&#160;March
      16, 2009</font></div>
              </td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="2%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
              </td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="36%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;Doug
      Ball</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Doug
      Ball</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief
      Financial Officer</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br><br></div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<TEXT>
<html>
  <head>
    <title>ex991.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">210, 1167
Kensington Cr. N.W</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left">Calgary, Alberta</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left">Canada T2N 1X7</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="ex9915.jpg" alt=""><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#1
60;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR
IMMEDIATE RELEASE</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics
Biotech&#174; Inc.&#160;Announces Reovirus Research to be</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Presented
at AACR Annual Meeting</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, --- March 16,
2009</font> &#8211;Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">announced
today that abstracts covering research with reovirus (REOLYSIN&#174;) are available
on the American Association for Cancer Research (AACR) website at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.aacr.org</font>, and on
the Oncolytics website at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.&#160;&#160;&#160;The
research is scheduled to be delivered at the 100th AACR Annual Meeting in
Denver, Colorado, April 18-22, 2009.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The first
abstract, entitled &#8220;<font style="DISPLAY: inline; FONT-STYLE: italic">Reovirus
Infection in Combination with Chemotherapy Improves the Efficacy of Treatment in
Primary Cultures of Patient Derived Epithelial Ovarian Cancer</font>&#8221; covers
preclinical work using reovirus in combination with cisplatin, paclitaxel and
gemcitabine.&#160;&#160;The combination of reovirus with chemotherapy induced an
additive effect in most cases, however a clear synergistic response was seen at
certain dose combinations in more than 30 per cent of the samples treated with
reovirus and paclitaxel.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
investigators concluded that the data supports a significant synergistic effect
of reovirus and paclitaxel.&#160;&#160;A poster presentation is scheduled to be
delivered by Dr. Geoff Hall and his research group from St. James&#8217;s Hospital in
Leeds, U.K., on Sunday, April 19, 2009.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
second abstract, entitled <font style="DISPLAY: inline; FONT-STYLE: italic">&#8220;Clinical Evidence of Reovirus
Oncolysis in Human Prostate Cancer&#8221;</font> reports on early clinical work using
reovirus in a small cohort of prostate cancer patients prior to
prostatectomy.&#160;&#160;Six prostate cancer patients with cancer confined to
the prostate gland received a single injection of REOLYSIN&#174;, followed by
prostatectomy several weeks later.&#160;&#160;Intralesional reovirus injections
resulted in minimal side effects, and evidence of anti-tumour
activity.&#160;&#160;There was no evidence of viral spread to adjacent normal
prostate tissues.&#160;&#160;Evidence of reovirus spread to other intraprostatic
cancerous lesions was not observed.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
investigators concluded that reovirus therapy may provide a novel treatment for
prostate cancer, however, ongoing work to circumvent immune clearance of
reovirus is required.&#160;&#160;A poster presentation is scheduled to be
delivered by Dr. Don Morris and his research group<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>from
the Tom Baker Cancer Centre, Calgary, on Tuesday, April 21, 2009.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About
Oncolytics Biotech Inc.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics
is a Calgary-based biotechnology company focused on the development of oncolytic
viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical
program includes a variety of Phase I/II and Phase II human trials using
REOLYSIN&#174;, its proprietary formulation of the human reovirus, alone and in
combination with radiation or chemotherapy.&#160;&#160;For further information
about Oncolytics, please visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">This
press release contains forward-looking statements, within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. Forward-looking
statements, including the implication of the abstracts and materials presented
on the AACR website and at this meeting with respect to REOLYSIN&#174;, the Company&#8217;s
expectations related to the results of trials investigating delivery of
REOLYSIN&#174;, and the Company&#8217;s belief as to the potential of REOLYSIN&#174; as a cancer
therapeutic, involve known and unknown risks and uncertainties, which could
cause the Company&#8217;s actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among others,
the availability of funds and resources to pursue research and development
projects, the efficacy of REOLYSIN&#174; as a cancer treatment, the success and
timely completion of clinical studies and trials, the Company&#8217;s ability to
successfully commercialize REOLYSIN&#174;, uncertainties related to the research and
development of pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should consult the
Company&#8217;s quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements. The Company does not undertake to update
these forward-looking statements, except as required by applicable
laws.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR
FURTHER INFORMATION PLEASE CONTACT:</font></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics
      Biotech Inc.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cathy
      Ward</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">210,
      1167 Kensington Cr NW</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary,
      Alberta T2N 1X7</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:
      403.670.7377</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:
      403.283.0858</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">cathy.ward@oncolytics.ca</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td align="left" valign="top" width="26%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
      Equicom Group</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nick
      Hurst</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">325,
      300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>
      Ave. SW</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary,
      Alberta T2P 3C4</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:
      403.538.4845</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:
      403.237.6916</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">nhurst@equicomgroup.com</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td align="left" valign="top" width="28%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
      Investor Relations Group</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Erika
      Moran</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11
      Stone St, 3rd Floor</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">New
      York, NY&#160;&#160;10004</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:&#160;&#160;212.825.3210</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;212.825.3229</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">emoran@investorrelationsgroup.com</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-30-</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br></body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex9915.jpg
<TEXT>
begin 644 ex9915.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@`Z.#$!`@`0````3@``````
M``!X`````0```'@````!````4&%I;G0N3D54('8T+C`P`/_;`$,``@$!`0$!
M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`%$!
M4P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHK+\7>+O#?@/P[>>+O&&MVNFZ7IUNT]]?WDPCB@C49+,QZ"
MDVDM0-%ID1<CGZ5A^-?B1X"^'>F?VQX_\:Z3HMKN"BYU;48[>,DG`&Z0@<GB
MO@KXX_\`!4+X]?'[XF7'P$_8!\#273.[1Q^)A:B6XN%'WI8DD`CMXASB27)/
M!PO0U?`'_!&?XM_%C4D\=?M>?M!WTM]<`R7-EIT[7MTI;=N4W-P2BD?(?E1E
MSD<@!J\^6+E4?+1BY>>R-/9I?$['U0?^"D_[#4<C1O\`M(^']RL0</(1^83F
MMGP/^W/^R#\1M4.B^#OV@_#%S=[HU6"745@9V=MJJOF[=[$G&%R:\CL?^"+_
M`.Q+;6<5K=:9XFN98XE62Y?Q%(K2L!RQ"`*">N``.>!6)\1/^"(?[*WB'1S;
M>`/$7B3PY?H6,=VU]]MC)(P-\<HY`Y^ZRGGDT<^/M\*^]B?LNY]EVE[:7L"W
M%E=I+&WW)8G#*WT(X-3EU(XYK\K_`!S^SM^WG_P3#U4?$?X,>/[CQ)X+MI`U
MXEHDCVR0K("%N[-B1&IW']Y$>-SG<F>?JW]AW_@IE\+?VLHH?!'B*"+PWXX9
M7;^Q'E9H;U4QF2VD(&XX.3$?G7:Q^8#=5TL9"4^2:<9=GU]`E3:5UJ?4M%(C
M;E#>HI:[B`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`&R'*'/'UK\Q/VQ/C3\3O
M^"D7[2,'['W[.S/#X;T&^F&J7TESBWO7AD59+V8+UAB/$:\EF8'&2`OUS_P4
MI_:#U3]G7]E+7?$WARY$.LZNR:/HTN6#1S3Y#2*0.&2)97&2!E`,Y(%<!_P1
MV_9PL?A/^S3#\5]3L<:WXZ87CR2I\T=BI9;=!_LL,RYYW>8OH,>;B7*O7C1C
MMO+T[&D?<7,>X_LN?LK?"S]D_P"'T/@/X::0!)+MEU?59LM<:A<!0#([$DA<
MYVIG:HX'J?45QDD'K0%P,$T$A17="$:<5&*LD9MMN[%HHHK0!DJK(A4J"",$
M&OS\_P""EO\`P3N\/>$_#<O[4_[+F@3:#KNA7:W^N:?H;/&IB7&;JWCC'[J6
M-L2,5*@J&8C(Y_08$'D55O;2VO[>2UN[>.6&5&26*5`RNI&"I!X((X(-<M>A
M&M'7?H^Q49.+NCYO_P"":O[:2_M;?"!K/Q5*5\7>&%BMO$!.T"]#*?+NT"@8
M#[6R,##JP&1@U],E<DU^6/CKP?-_P37_`."FWAW5_!4[P>$/%MVC1V4;*VVQ
MNYA%/;%!M^6*7#Q],`1C)P^?U,1L@\=#6."K3E!TY_%%V8YQ2=UU'T445Z!`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`?G3_P`%V];NKJZ^&'PW=%6UNYK^[>X4'S%8
M&"'`YQC$I/3J!VXK[[\!^%M/\#^#M+\&Z0%%KI6GPVMOA%7Y(XU0'"@`9`SP
M,5^?W_!=;3+^#Q1\*_&DMOMTZW_M"WGN-XPLADMI-N/O'Y48\#MZX!_0SP[J
MMCX@T2TUW2Y_-M;RUCGM9=I&^-U#*V"`1D$'!KS<.E]=J7\ONL:/^&C0HHHK
MTC,****`"BBB@#X"_P""\'A#0Y?A1X'\>-;XU.V\1RZ?%,H`S!+;O*RGC)P\
M"$<\9;^]7V)^SCKFJ^*/@!X(\3:]>FXO=1\(Z;<WDQ4+YDKVR,S84`#))/`%
M?(__``7@U33XO@3X*T66\C%W-XN>XAMBXWO%':2H[@>BM+&">V\>M?6'[+T5
MS:_LV?#ZRN[:2&:'P3I22Q2H59&%I&""IY!&.AKSZ3MC9^B*?\)'EG_!3G]I
MWXH_LH?`S2_B#\)FTU=1O/$\-A*=4LS.GE-;W$APH9<'=&O.?6O-OV(?^"G/
MB+Q_XZ'P,_:SL;#0O$NI>5/X9U:UC\FRU**95>&/EF`9U8-&X8K(&`&&P&G_
M`."YYW?LI^'^<?\`%=V_/_;I=UC>+_\`@GMX8_:X_8<^&'C+P@8-*\?:5\/-
M,_LS4C\B7R);(5MIR.V?NOU0G^Z2*RJRQ'UI\C^%;=RO=Y+,^EOVROB+\1/A
M!^S3XM^)_P`+KW3K?6=`TPWT+ZG:M-"T<;JTJE%()9H]X7G`8@FN/_X)J?M(
M?$G]JC]G>;XG?%=[!M33Q'=6*_V;:&&/RHTB*_*6;G+MSFOD'0_V[?'M[^R]
M\3OV+/VK+"\L_&NE^$KZUTC5-0!$MT8HB?LUP3UE"#*2Y(E7')8@O]!_\$11
MG]C.XY_YG2__`/15O2IXGVN*BDW:SNO.X.*C"S1]9:YKFC^%](N?$&O:E!96
M5G;O-=WEU*(XX8U&6=F;A0`.2:^/!^WW^T7^UGXUU#P%^P!\+=.DTS2+@+J7
MCWQ@S"S.&X6.)>1O4$KNRQ4D[5QD^D_\%3/"_CSQC^Q+XPTGP!%)+<1QVUQJ
M%I!;&62XLX[A'E154$Y`4/D8X0\BO*_^"(GCCX:2_LZZEX`TC68E\3P^(+F^
MUC3)KM#*\;+$D=Q'&/F$6U40DC'F*_/(K2M5D\0J2=DU?_AF))*-SO9_`G_!
M6"Q$VHVOQQ^$=VXA'E:>_AR[2-F7<=H;.5+9"DDD``8`P<^V?!"Y^.UYX-%[
M^T#IGANRUV2=R;+PM+/);PQ#A09)CEW."3@*!D#G&3VBJ&`.ZEV@'!&<UTTZ
M2B[W?WW);N>??M'?M&?#;]F#X:W?Q.^)FL&"T@_=V=G$09[^X(RD$*G[SG'T
M`RQ(`)KYV^$/Q[_X*.?M?Z1%\4O@[X6\"?#OP?<PL-+?Q4L^H7%^P?:7'E[-
MJ9#8)5<XXW`ACRG_``79\$^+M7^$/@SQIITM[)I&DZ[-'JUK#;LT4331`17$
MC#A-I5HQD8)FZ@XS]%?\$^?'O@[XA_L?^!-4\$VUM;6]EH$.GW5E;MG[+<P*
M(Y8SD#!W`MTP0X()!!/*YRJ8MTI-I)7]?^&*2M#F."\4P_\`!6;P#HTGBNQ\
M1_"OQH]GAV\-6&CW5I->+T(2620*",[L$C.W`/-7_P!BW_@I/\.OVL-<D^&^
MJ^%KWPQXRM+62:XT>[<20S",@2>3)P25)Y1E#``GD`D?2SL!T].:_)W]E^$>
M//\`@L'?:_\`">]>WTR+QAK5]<7$<QF6:T59A+\Z*!LE=LJ",`2(N6X)FK4G
M0G%0E?F=M=1Q2E<_6565B'S7QM^P+^VS\<OVC?VFOB)\*?B5+H[:3X86[;2Q
MIVFM#*#'?&!=[;V#?)[#GFOLA0-N['O7YN_\$B<?\-S_`!FQQ^[O_P#T[&ML
M1.<:M-)VNW?[B4E9GZ2U0UVTU*\TBZM-&U06-W);NMM>-")1#(0=KE"0&P<'
M&1G&,BKS-CM0PW*5S7=HT2?`H_X*)_M,_LK?M,GX0_MV:'I+>&[X8T_Q)X>T
MJ2&/RR^%NUR[^9'T$D?WX^3@X^;[,\7?&3X8>!?A?<?&3Q/XUL+?PS!8"\;6
M!<!X7A891D*Y\PMD!0N2Q(`R:Y[]J+]EWX8?M6_#*Y^''Q)TX[DW2Z3JUN@^
MT:;<[2!-$3^14_*PX/M^9'[.G[.WQ&^/O[1,O[`'Q$^,^H/X+^'NKZE>W-G;
M2MY<OV>=()!`&R4+LPQNR(PTC*-S'/DU*E?#3Y'[RE\/KYFEE)770^MOV7/V
MN?VNOVU_CAJ'B7X9:)I/A?X0Z3?".2_U;26FO;T(>88W\P+YK]6P"L0(!+-C
M/TO\<]-^.6K>"/L?[/GB?0=(\1+=QL+SQ+8R7%KY'/F*4C(;<>,'H,&MSP!\
M/_"'PM\)V'@'P)H%OIFD:9;K!96-JFU(D'\R3DDGDDDDDFMWH>U=M*E.-.TW
M=O?_`"1#:YKH^,OVA_&W_!3K]G/X.ZU\:O$_Q<^%=_9:%#')<6=EX8NQ+('F
MCB`7=(!U<'GTJE^R_P#%/_@IE^U5\';'XS>$_BI\+M,L;^YN88[34O#%T95:
M&9XF)V2$8)7(]CS7J_\`P5+!_P"&#OB$6/\`RXVG_I=;U@?\$=@3^PAX;`_Z
M"NJ?^ELM<G+)8M0YG:U]R].6]CU[]GW1?VD=&T"_7]I3QMX9UO5)+P&P;PMI
MDMM!#`$'#>:2S.6SSTP![UYS_P`%,/VD_B;^RM^SW;_$OX3OIR:G+XDMK%FU
M.S,\?E/',S?*&7G*+SGUKZ*`"#DU\=?\%P?^3.['_L=K+_T1<UTUY2IX>3B]
M4B8?$>P_L(?&GQS^T-^RUX9^+OQ&ELVUC5?M8NVL+8PQ?N[N:)=JEFQ\J+W/
M-=-^T+^T+\-_V9_AM>?%+XH:T;6RMQLM[>/#3WLY!*00IGYW;'T`!)(`)KS+
M_@E197EC^PCX&COK26!WCOI$66,J61[Z=E89ZAE((/0@@BO%?^"Z_A7X@ZM\
M)?!OB?0K2XFT#1]:N3K?D[BD,TD:+;S2``@`8F0,2,-(H_BXR]M.&$4]W8.7
MWK'0_#?]JG_@H'^V1)#XM_9M^$OAWP'X,61A'KGCGS;E]14LX#Q+&%#*-@!V
M@@%B`[8Q7=-HG_!5GPV?[6_X37X/>)A'Q_8S:;?60ER<;O.!.W;G.,<XQ76_
M\$^?$WP\\2?L?>!/^%97L<EG8^'K>TNH5FW/;W:(/M".-Q*MYN]MI.<,.@KV
MPY.2>W:JHP<X*3FW?L]`O9V,3P(/'*^%+%_B/_9HUPVRMJ:Z.)!:K*>66+S"
M6*CID\G&<#.!\O\`[;O_``4B\1_L\_&W1/V<_A/\-K+5O$FJBS:2^UV[>*RB
M^TRF.)!Y?S,202S$@*,<-SCZ]KR?]I+]C_X"?M5:9'IGQ>\$1W5U;1%+#6;2
M3R+VT!.2(Y5YQGG:VY<\E36M>%25*T)68DTG=GF4_P`/O^"JFNWT&OR_M!?"
M_2#"3)'HMIX;N)K>7S.L4TC_`#L(QG:R%=Q'/!KI/@M?_P#!16W\:66@?'G0
M_AC-X?CGF_M#7=$O+M+N:,;O+\N`C:I)V#YB>,]Z\HN?^":_[4?PSLWMOV<?
M^"@/BNPMHA"]OI7B(O-&70@8,BN0D>Q0`@B(.,'@\>?VG_!03]L_]EC]H;3_
M`-G#]IW2O#WC5KN_M8S?Z&@2[D@N965)$$05-^64^6\:G"]]P:N.-7V+3FFK
MNV]T7R\VQ^C`&!@4445ZQF?*G_!7+X$77QF_9*O]=TG33<ZKX.NEU>V6)07-
MNJE;E1P?^63,^!U\L#-:7_!*SX_VGQP_9)T33KK5#-K?A.-=&UA)"3)B,?N)
M"2Q+;X=GS9Y97Z8P/I"_M(-0M9+*XA22*5"DL<BY5U/!!'<$9%?EQXHM?B1_
MP1]_:\D\8:3I;:K\-O&4TWD:?;S$>;:!PWDD?=6YM]_R$_*R,1D;CM\RNOJ^
M)C6^R])>79FD?>C8_5#(/0T5S'PL^*?@/XS^"K'XA?#CQ':ZII.H0AX+FVG5
M]I_BC?:3M=3PRGD$8-=/7H1DI*ZV,PHHHJP#@BD9E7J:4G`S7RK_`,%&/^"@
MV@?LI^"I/"'P]U73=0\>Z@#%;V+3K(=)C9"?M4\8YQC&Q#C<2#RJFL:U:%&'
M-(:3D[(^9?VZ-=3]N+_@HUX4_9O\')+=:5X>NTTO4YH9&:/.\37TF`R@".-?
M++`AB4(&?ES^G6GVD=E:QVD2[8XHU2,9SA0,`9[U\9_\$F_V+M6^$OABX_:3
M^+%LY\8>+[8O9QW0D\ZQLY6$C&4.`1/*P#MGD#`S]X5]J*<9!/`KDP=.HU*I
M/1R=_ET+G)/1=#Q_]LC]DGPU^V3\-[+X9>*_%NHZ+;6.LQZC'<Z9'&TCND4L
M84^8"`,2$^O%=U\'OAU8?![X6^'OA=I^ISWEOX>T:VTZ"ZN`!)*D,80.P7@$
M@9..*^6?V[?^"BOQ7_9G_;;^#_[(GP\\':7<0?$SPUKNJ7FO77AC5M:N+)M/
M6-E2.QTS,TH?>06Z)U/`-=7^P!_P4*;]K3QU\1_@CX]\.VFA>-?AOK$=O=V/
MV>\T^?4[&5%>'4%TS4(H[RTB8.BYD#(S9V2-@A>U4H*?/U,S?_;%_P""=OP8
M_;&O+'Q#XENKO0-?L=L8U[1XX_.N+<9Q#*K@JX!.5)&Y>0#@D5U?['_[*WA[
M]D#X42?";PSXJOM8MGU>>_-YJ$4:2;I%0%<1@#`V#'?FO5P5*XQ^%?.'[3O[
M<FL?`7]MS]G7]D32O`-KJ$7QNU/Q#%J&N7%ZR-I<.F:;]J'EQA<.\CO&,D@!
M5;@DC$+#TU4]HEJ-MM69]'F)6!5L$$8((KYA^*W_``2O_9_\9>,&^)GPQU;7
MOAOXD=R[ZEX*O_LR.S,"Y,1^5=V#D(5!W$D$U]05XI^WY^V#8?L(?LI>+/VI
M-6^&.M^+X?#%FLAT/0E`DE=W6-6ED8%;>W4L&EG;*Q(&8AL8JIT:=5>\K@FU
ML<M;?L-_&6.YB>__`."@WQ9N+=9%\^!;BT0R)D;EW"+*DC(SVSGM7J7P%^`.
MG?L_Z#=^&-&^)'B_Q#:7-P)XQXOUS^T)+=L881R,@<*>"5)(STQDY^?OVA_V
MXOVM/V3_`-G.^_;2^*?P1\`:WX!TS1K75->T+PMXRN?[7TJVDFB1S!-+;&WU
M4A)"X`^R@E0JE]VZOJOP7XILO''A73/&&DV]S%::MIT%[:QWENT,RQRQJZB1
M&&4<!AE3R#D'D4J=&%/5`VV2^*/"^A>,]`N_"WB?1[;4-.U"V:WO;*[B#QS1
M,,,C*>""*^:K;_@EYX4^'_B"?5_V:_V@/'WPTM;R,"^TG0=36>WE<;?G`N`Y
M!^4=23Z$#BOI'Q<GBF;P[?1>"+C3XM6:V==.EU6!Y;9)B/E,B1LK,F>H#`GI
MD5\>?`/]M3]MCXS?MW_&/]BF[LOA99'X,6WARZU'7XM*U)_[6BU2V:X*1Q&Z
M_</&J%<LSAB<X`!%$Z%.<N9K4$VCLK__`()[?&3Q'I$GA_QE_P`%!OBG?6ET
M"EY!#);PK+'NR%R%W+Q@$@\G/`!Q7K/[./[)'P+_`&6=!DT3X0^#8K*6XC1+
M[5+AS->7FWH996Y(R20HPHSP!7IRMN&<=Z\Z_:W^,>J_L\?LM_$?X_Z'HUOJ
M-YX'\"ZMKUKI]V[+%<R6EG+<+&Y7D*QC`)'(!-*.'I0=T@;;/1<#''I7QYX=
M_P""3%IX$^)&M?%+X9_M7^._#&J:Y=W,MW+HT=LGR32F5HN4.Y0QXSD\`]>:
MV_V+OVK?VB?VAY?#>I?$2UT:PMM3\.1ZIJEA9_";Q1IJQ&2%66*'4=26.WEV
MO(G.T%U#%5&,CZH)4C)HJ4856G);;`FUL?-)_83^."C"_P#!1CXLG_MI9_\`
MQNO>_`_AF]\'^$]-\,W_`(BOM8FL+*."75=3FWW%VZKAI9#_`'F.2<<#.!@5
MY5^WG^VEX5_84^"UO\5O$WA.ZUB;5?$-CH6BVJS_`&6T%]=S+%$][>NIBL+8
M$Y>>3@8`4.[*IZ3X/7W[46J:Q<:O\<HOAY8:7.DATW2/"%Q>WL\/SC8SWLZP
MI,"@).VWCP6`R0I+7&E&#T$>FD9&*^>_@K^P%X-^"O[4/BC]J32O'VK7VH^*
M#?FYTJZ@A6W@^U7"3MM*C<=I0*,GH>:^@PV3@5X!^WI^V5J/[&>G?"_6[;P'
M=>(+7QS\6=-\)ZI;Z=I]S>7EM;7-O=2M<6]O;*TD\B&W7Y`I.TL<'%3*E&HT
MVKVU0TVCZ`HKXX\<_P#!4CR/^"@WP%_8W^'_`,,-8;2OBS;^)9-:UKQ=X0UC
M1+BP;3;`7,0M4OK>%;@.25?&[9QG&X9^QZV$<#^TE\#],_:0^"NN?!;6]=N=
M-M-=ABCFOK-%:6()-'*"H?*G)C`Y]:H_LI_LY:)^RK\&]/\`@SX<\27FKVFG
MW-S,E]J"(LKF:9I2"$`7`+8&!VKTRBL?90]IS]0"O)/VPOV5/#_[87PKA^%/
MB7Q5?Z-;0ZO#J"WFGQ1O(6C210F)`1@^8<]^*];KYH_92_;?\6?M"_MP_M(_
MLIZUX(TW3M.^"&K>'K32=5M)Y&GU)=1T]KIVF5OE0HR[1MZCK53A&<7&6S`]
M:_9O^"\'[/7P:T3X.VOB[4]<@T.!XK?4=593.T;2NZH=O`5`P10.`J@#@5U?
MB+PWH?BO1+OPUXETFWOK"^MW@O+.[A$D4T3##(RG@@CM6E7R]^W-^VM\=/V:
MOCM\+OA7\%/V?[?XA?\`"7:3XCU;7=(@U(V^J26>E1V;O%IP8>5+=,+HLL<K
M(K^5L#JS`TE2BHJ/1`4[K_@E;\/O"GCNX\>?LW_&GQK\,)+U&%YI_AF_5K=R
M3_"LH.U1SA<D#/R[:TW_`&`?B!KA_LWQ_P#MW?%[5M+;F:R@U:&S9V'*D2PQ
MAUP<'`Z].F:YC]FS_@J5HO[5G[;>D_L]?"?P#*W@C4_@M/XQ_P"$KU-)K>]@
MU6'5(+*XT::U=!]GGMQ*K3(Q+*98^`K`M]@U"P]&.B17,SFOAAX`B^&'@+3?
M`5GXFU?5XM,M_)BO]?OC<W<JY)'F2D`N0#@$C.`*\C^.7[`_ASXV>-M3^(TG
MQX^)GA_5]1M8X(CX>\5M;VMLL:D(%@5<%02S$$\L['O3_P!MW]N'3OV0=1^&
MG@ZU\##7/$7Q7\>0>%?"R:AJ36&F6]RZ&1I+R\$,Q@78I"*L;O(Y"A<;F7O/
M@I=?M$S6=S=_M"S^"([J<1O8V'@Q+MTM`2V]'GN6!N,?*`ZQ19()*#(`TE2C
M./*UH)-K8\>/["G[1*:JI3_@HW\3OL`M<>7Y=J9S-NX.\KMV;<C;MW9YW8XK
M7^!__!-?X"_!_P"(C?&3Q!?:QXU\923+<R>(/%MREPZW08DW,:!0$DZ#=SM"
MC;MKZ,J.:>.)E5B`6Z`MBLUAJ*:=MA\S)`,#`HHHKH)`@'J*XCX[?`CX;?M&
M_#N^^%_Q3\/I?:9>KE6!VRVTH^Y-$_5)%/((]P002#V]%9RC&<7&2NF!^8&N
M?`C]NC_@E[\0-3\:?L[I>>+OAU/<&>YLQ$;A'3:/^/NWCP\<BCY?/CPIP"W'
MR5[C\$/^"T_[,_CK2[:W^+EOJ'@S568I<B6U>[LP0I)=98E+!3MP`R`@L!SU
MK[),:'KT!SFO%?BS_P`$]/V/?C,[3>,?@EI,%T\QDDOM$C.GS2,6W,7:W*;R
MQ)R6R3DUP?5J]*5Z,M.SV7H6YQEN;,?[;O['LD8<?M->!AN`(!\3VPZ_5ZP?
MB'_P49_8N^'.C?VQJ?[0.A:@#D1VN@W/V^:0CL$@W8_X%@'M7D,G_!#?]DZ1
MR8_'/CI5+$JO]JVIVC/3FV_"MCP1_P`$7_V-?"6IG4M9A\3>(@KHT=MK&LA8
MD*MD\6Z1;@>A#$C';FASS!Z**7S%:!Y#\9_^"PGQ.^+7BB/X0_L._"F]N;^_
MF\FUUC4K(374I+!0\-MDI&O(/F3$@`Y95KK/V)?^"6.L:+XQ3]H[]L;4VUWQ
MA->O?1:%<SBXAAN&8,MQ<R<B:8$$A1E%^7J5&/K?X4_`'X,?`[3FTKX1_#;1
M_#\3KMF?3K)4DE&21OD^^^"3C<3C-=BJ>6I!;)-53PDY24ZLN9]NB#FTLAT8
M8("_7'-.HHKT23S+XU?LC_L]_M">*]"\=_%CX;PZAKOA>.YC\/:_:W]Q97^G
MQW"A9TBN;:2.5$<`!E#8..E;?PL^!/P=^"MM=V?PF^%V@>&TOI1+?MHNDQ6[
M7<F`/,F9%#2N0!EG+,<<FNRHH`*XWQM\"_A)\0_B#X2^*WC7X>Z;J7B3P)>7
M5SX0UJZM\W&E27,#6\YA<8*^9$Q5AR#P2,@$=E10`V/=Y8##!K.\3>&/#WC7
MP]?>$/%NAV6JZ3J=G+::GINH6J3V]W!(I22*2-P5=&4E2I!!!(-:=%`'D&F_
ML(_L<:)J%K?:;^S)X(0V$\<^DPR>'8'@TV5'#A[6%E,=JQ<*S-$J%F568LP!
M'K^`.@HHH`"`>HKC?#GP)^$7A'XL>(OCEX:^'FEV'BWQ=965IXFUZUM]EQJ<
M5H'%LLQ'#^6)'"DC."!G``'944`%8?Q"\!^$_BGX$UGX:>/M$AU/0O$.EW&G
M:SIMR"8[NUGC:.6)L$':R,RGV-;E%`'SY\#O^"7'[!/[-/Q&T[XM?`S]F[1_
M#GB'28Y4T[4[.\NF>W62)HG"K)*RX,;,N,<`\8KZ#HHH`Q_&G@KPA\1_"]]X
M'\?>&-/UO1M3MFM]2TG5K)+BVNHFX9)(I`5=3Z,"*X?X5_L>?LS?!#Q.WB[X
M4?!'P_H5]OG:VFL;(`6`F_UR6JG*VB2'YGCA"([99@3S7J%%`!7+?$+X1_#S
MXJW?A^\^(/A2UU27PMXABUSP\]R"38ZA%')''<I@CYU2:0#.1\YXKJ:*`.,\
M3_`?X2>,OBOX:^./BCP!IE_XL\'VE[;^%M>NK??<:7'>+&MR(23A#(L2*2!G
M`(S@D'LD&%`/7%+10`4444`%<9X)^!GPD^&GCKQ9\3?`/P]TS2_$'CO4+>\\
M8:Q9VP6XU6:"%8(6F<Y+;(E"JO``S@98D]G10`5RWB'X1?#KQ5\2/#_Q<U[P
MK;77B7PI:WMOX=U>7/FV,5X(UN43G&)!#&&R#]P8Q74T4`>>:-^R_P#`/0?V
M@=0_:GTCX5:/:_$+5M#&CZIXKMK;9=7ED'C812D'#\Q1?,1NQ$BYPH`]#HHH
M`YOXE_"KX;?&3PL_@3XN?#[1?%&C331RS:3X@TJ&\MG=&#(YCF5E+*P!!QD'
MD8KE/A-^R%^S?\#->?Q+\)?@UH6AW["=8;FSM?FM8II/,E@M]Q/V:!G^<PQ;
M(RY+;<DD^GT4`%<CX\^"GPL^*'B7PYXL^(/PZTC6=2\(W[7WAJ]U.R29].N&
M`!EAW#Y'PJ\]BJD<J".NHH`****`(Z***`"BBBI[`%%%%/J`4444H[`%%%%4
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
:1110`4444`%%%%`!1110`4444`%%%%`'_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
